Taste, a new incentive to switch to (R)-praziquantel in schistosomiasis treatment - Wikidata - wikimedia - TriplyDB

Taste, a new incentive to switch to (R)-praziquantel in schistosomiasis treatment

Taste, a new incentive to switch to (R)-praziquantel in schistosomiasis treatment

http://www.wikidata.org/entity/Q21090121

about

Open science is a research accelerator Resolution of praziquantel Single Versus Double Dose Praziquantel Comparison on Efficacy and Schistosoma mansoni Re-Infection in Preschool-Age Children in Uganda: A Randomized Controlled Trial Pharmacokinetic Study of Praziquantel Enantiomers and Its Main Metabolite R-trans-4-OH-PZQ in Plasma, Blood and Dried Blood Spots in Opisthorchis viverrini-Infected Patients Structure-Bioactivity Relationship for Benzimidazole Thiophene Inhibitors of Polo-Like Kinase 1 (PLK1), a Potential Drug Target in Schistosoma mansoni Open source drug discovery - a limited tutorial Putting the treatment of paediatric schistosomiasis into context.Treatment of intestinal schistosomiasis in Ugandan preschool children: best diagnosis, treatment efficacy and side-effects, and an extended praziquantel dosing pole Design and synthesis of molecular probes for the determination of the target of the anthelmintic drug praziquantel.Closing the praziquantel treatment gap: new steps in epidemiological monitoring and control of schistosomiasis in African infants and preschool-aged children.Activity of praziquantel enantiomers and main metabolites against Schistosoma mansoni.Metabolic profiling of praziquantel enantiomers.Praziquantel in a clay nanoformulation shows more bioavailability and higher efficacy against murine Schistosoma mansoni infection.The cytotoxicity study of praziquantel enantiomers THE SUSCEPTIBILITY OF RECENT ISOLATES OF Schistosoma mansoni TO PRAZIQUANTEL.Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs.Antiparasitic drugs for paediatrics: systematic review, formulations, pharmacokinetics, safety, efficacy and implications for control.Diagnosis and treatment of schistosomiasis in children in the era of intensified control.In vitro and in vivo activity of R- and S- praziquantel enantiomers and the main human metabolite trans-4-hydroxy-praziquantel against Schistosoma haematobium.What is the mechanism of action of praziquantel and how might resistance strike?Praziquantel for Schistosomiasis: Single-Drug Metabolism Revisited, Mode of Action, and Resistance.Phenotypic, chemical and functional characterization of cyclic nucleotide phosphodiesterase 4 (PDE4) as a potential anthelmintic drug target.Enhancing the usefulness of cross dehydrogenative coupling reactions with a removable protecting group.Synthesis and SAR studies of praziquantel derivatives with activity against Schistosoma japonicum.The anthelmintic praziquantel is a human serotoninergic G-protein-coupled receptor ligand.Validated capillary electrophoretic method for the enantiomeric quality control of R-praziquantel.Accelerating the semisynthesis of alkaloid-based drugs through metabolic engineering.Drug Repurposing for Schistosomiasis: Combinations of Drugs or Biomolecules.Activation of host transient receptor potential (TRP) channels by praziquantel stereoisomers.A Rapid Appraisal of Factors Influencing Praziquantel Treatment Compliance in Two Communities Endemic for Schistosomiasis in Côte d'Ivoire Extrapolation of praziquantel pharmacokinetics to a pediatric population: a cautionary tale A comparison of the palatability of racemic praziquantel and its two enantioseparated isomers in yellowtail kingfish Seriola lalandi (Valenciennes, 1833)

P2860

Q21004179-66E6D2F5-3997-4143-950A-071CB0CFBDB5 Q21144507-208A8F4D-0757-499F-9200-BBE902DEE32A Q28547483-7884AB50-4485-4211-833A-8F7D76274348 Q28551880-A9A9A3FF-A56D-4DD3-B108-479D24607CDA Q28552326-8B00905E-8294-429A-8B65-E055C828CB3A Q28660808-17CA2482-9A48-4EB9-8855-37F300B8E851 Q30234902-6078019D-392E-420F-A443-67EDC59FD93A Q33635360-F978CA2E-5DDF-445C-8A3B-5D6366325468 Q33747366-45CC01B7-D14D-4260-AC47-C723B10EF31F Q34001292-9C10F7A9-A3D5-48CF-B7B6-5E1748B5F197 Q34057535-F0AB901A-E551-436D-9908-14BA2663D843 Q34208792-D25E122B-362C-4BBA-AAAA-F2B33A7FB8A8 Q35607817-086E25FF-E87C-42EB-AE71-05D808B6E6D2 Q36083496-BD31EC62-E69C-41AF-8908-57F572BE308C Q36692301-9566FEF3-6539-4285-8F4B-C5992541F16B Q37413446-993FF67E-C495-4A20-813F-1957E23FFE95 Q37846890-B57053DD-BA16-4779-A53D-BD721DB04142 Q38152776-2C980A77-FB9F-4BA3-AED0-A7D67EADF124 Q38648427-500ADBBD-4C4C-4C58-8206-06338EC88400 Q39004186-36830947-29A7-45CE-BA1B-53C24C171441 Q39164325-58A35338-9B85-48CA-BE20-75DCCED9376A Q39188232-2ECA1666-0A65-4404-9022-70CB585296F7 Q39535453-DDFE685E-7992-4069-9B92-157E7DA8935D Q46081944-D088E4B6-6509-4593-A8E7-847FCC74FB2C Q46247381-39316C25-D2AB-4CBA-B1A1-50E8A7ABC91B Q50881127-C2D5D3DD-488E-4926-94AA-B3E3B69A2CEB Q51003523-E3C31748-2BF0-46C1-917F-FD70FC8D47CD Q52699502-53EB79F2-0DA3-44D3-8E22-3A50709333B0 Q55222741-72044E1B-AB05-4E37-94B8-9FC1C9F24E1F Q57143687-29970525-B2F5-4655-A224-691B5F91737F Q58738240-7136D5F9-88FB-4AC3-AF34-01FA29F956C6 Q58864744-E836C436-2CAA-4E68-8C5A-6367099148F5

P2860

Taste, a new incentive to switch to (R)-praziquantel in schistosomiasis treatment

http://www.wikidata.org/entity/Q21090121

description

2009 nî lūn-bûn

@nan

2009 թուականին հրատարակուած գիտական յօդուած

@hyw

2009 թվականին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Taste, a new incentive to switch to (R)-praziquantel in schistosomiasis treatment

@ast

Taste, a new incentive to switch to (R)-praziquantel in schistosomiasis treatment

@en

Taste, a new incentive to switch to (R)-praziquantel in schistosomiasis treatment

@en-gb

Taste, a new incentive to switch to (R)-praziquantel in schistosomiasis treatment

@nl

type

label

Taste, a new incentive to switch to (R)-praziquantel in schistosomiasis treatment

@ast

Taste, a new incentive to switch to (R)-praziquantel in schistosomiasis treatment

@en

Taste, a new incentive to switch to (R)-praziquantel in schistosomiasis treatment

@en-gb

Taste, a new incentive to switch to (R)-praziquantel in schistosomiasis treatment

@nl

prefLabel

Taste, a new incentive to switch to (R)-praziquantel in schistosomiasis treatment

@ast

Taste, a new incentive to switch to (R)-praziquantel in schistosomiasis treatment

@en

Taste, a new incentive to switch to (R)-praziquantel in schistosomiasis treatment

@en-gb

Taste, a new incentive to switch to (R)-praziquantel in schistosomiasis treatment

@nl

P1433

Q21090121-B7340B93-050A-4F17-AC56-219C4098D4CC

P1476

Q21090121-D1E238DD-355C-4589-9708-12979FD33013

P2093

Q21090121-9943E097-548E-4BEE-8CD1-FE204B21D1CD

Q21090121-BD7437A7-FDA9-4D12-84AC-94B3FA85E98C

Q21090121-C2332E09-81E5-43A5-8D76-06614A0219CA

Q21090121-C3971FF6-3807-41DA-B29C-4BADDC33483F

Q21090121-D350C48B-0AD6-42BE-B0A7-D568E076BF0E

Q21090121-F0CFC9DC-5FA2-47E7-88D7-CF5B1652010B

P2860

Q21090121-38ED41C8-9CC6-4BF9-9A9E-354F04BB5A12

Q21090121-5A488F85-512F-4182-84AA-30AB8761A759

Q21090121-772472E4-474B-4EC4-A766-DA0F9A91E451

Q21090121-8FB062D9-6270-4286-AAE6-3B3E64D96F1C

Q21090121-CEA5B7A8-0129-439C-A20D-7BB7285F1899

P304

Q21090121-76313500-A4B0-4C10-A520-84CD1C4ECF92

P31

Q21090121-F08ADFF3-E8A5-4F0B-A303-9BBD78CCC15E

P3181

Q21090121-547C182D-0263-4534-B2BA-D032EA5F3682

P356

Q21090121-6F313ABD-BC26-4EA4-9CE6-6A245111561D

P407

Q21090121-0B560482-1B97-45CD-ABFC-3FAF6C54B89F

P433

Q21090121-92EF39B0-1596-417E-AC84-E4B8AFF220C6

P478

Q21090121-33C01AB7-072C-4E44-A1B7-9845CED49907

P577

Q21090121-77BC7E47-3E9F-41D4-8B67-06AC4A1825E4

P5875

Q21090121-47786E80-EE88-43B4-A97B-70284B7B44B7

P698

Q21090121-5EA3D048-6962-4C9A-8CFD-A16FC6D6225F

P921

Q21090121-2A19357A-97A6-4902-8065-90B0106B3C8A

Q21090121-A55F3243-5B8C-4A11-A414-C96C19E13A09

P932

Q21090121-23879081-F162-4018-89AE-E4D84866922E

P3181

P356

JOURNAL.PNTD.0000357

P1433

PLOS Neglected Tropical Diseases

P1476

Taste, a new incentive to switch to (R)-praziquantel in schistosomiasis treatment

@en

P2093

Christian Miculka

http://www.w3.org/2001/XMLSchema#string

Dieter Schollmeyer

http://www.w3.org/2001/XMLSchema#string

Harald Sekljic

http://www.w3.org/2001/XMLSchema#string

Heiko Bothe

http://www.w3.org/2001/XMLSchema#string

Stefan Fuchs

http://www.w3.org/2001/XMLSchema#string

Thorsten Meyer

http://www.w3.org/2001/XMLSchema#string

P2860

Drugs for the control of parasitic diseases: current status and development in schistosomiasis.

A mass chemotherapy trial of praziquantel on Schistosoma haematobium endemicity in Upper Egypt.

Investigation of praziquantel metabolism in isolated rat hepatocytes.

In vitro responses of praziquantel-resistant and -susceptible Schistosoma mansoni to praziquantel.

P304

e357

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

519193

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PNTD.0000357

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23807599

http://www.w3.org/2001/XMLSchema#string

P698

19159015

http://www.w3.org/2001/XMLSchema#string

P921

infectious disease

schistosomiasis

P932

2614124

http://www.w3.org/2001/XMLSchema#string